Dermatology Times 2024 In Review: Hidradenitis Suppurativa

Phase 2a Study Demonstrates Dose-Dependent Tolerability of Oral Orismilast in Hidradenitis Suppurativa

Results of this study may also be indicative of oral orismilast's ability to contribute to meaningful clinical improvements, investigators noted.

Lutikizumab Demonstrates Positive Results in Phase 2 Trial for Hidradenitis Suppurativa

Higher response rates were observed in patients treated with lutikizumab and the drug advanced to phase 3 clinical trials.

Market Study Reports Secukinumab Emerged as a Leading Treatment for HS

To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists.

Investigating Intravenous Ertapenem Therapy for Hidradenitis Suppurativa

IV antibiotics should play a complementary role in the management of HS as new immunomodulator therapies are developed, researchers concluded.

Expert Insights Into the Relationship Between the Hippo Pathway and Extensive Fibrosis in HS

Researchers from the University of Michigan and Almirall found that the profibrotic fibroblast response in HS can be modulated through inhibition of the Hippo pathway.

More Research Needed Regarding Dietary Considerations for Patients With Hidradenitis Suppurativa, Review Finds

Findings regarding an association between HS severity and dietary elements such as vitamin D, B12 supplementation, and more, are inconclusive.

HS Excision Clinical Pearls Discussed at AAD Annual Meeting

How can you improve excision care for your patients with hidradenitis suppurativa? Ashley Nicole Elsensohn, MD, MPH, FAAD, shared clinical pearls at the AAD Annual Meeting.

Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy

Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.

Anticipated FDA Approval of Bimekizumab for HS: Insights From Investigator Christopher Sayed, MD

The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.

Surgical Procedures to Consider for Hidradenitis Suppurativa

Maria Aleshin, MD, FAAD, presented surgical procedures for HS that can be performed in the office.

Maternal Hidradenitis Suppurativa Linked to Increased Risk of Childhood Morbidity

Presented at the American Academy of Dermatology Annual Meeting, the poster was the winner of the second-place poster award.

UCB Receives Positive CHMP Opinion for Bimekizumab for Moderate to Severe HS

If approved, bimekizumab will be the first IL-17A and IL-17F inhibitor approved in Europe for hidradenitis suppurativa.

Hidradenitis Suppurativa in Transgender and Gender-Diverse Patients and Hormone Therapy

Researchers found that patients who initiated gender-affirming hormone therapy with testosterone were more likely to experience a worsening of their HS symptoms.

Incyte and CMS Collaborate to Develop Povorcitinib in Numerous Chinese Regions

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

FDA Accepts Supplemental Biologics License Applications for Bimekizumab to Treat HS

The submission stems from promising results from the phase 3 BE HEARD I and BE HEARD II trials.

MoonLake Immunotherapeutics and Komodo Health to Partner to Improve Research on Inflammatory Skin Conditions

MoonLake’ssonelokimab is being evaluated for hidradenitis suppurativa, psoriasis, and psoriatic arthritis.

European Union Approves Bimekizumab to Treat HS

The European approval was based on data from the Phase III BE HEARD I and BE HEARD II trials.

AI Chatbots Can Provide Support to Patients with Hidradenitis Suppurativa

A novel study assessed the potential of 2 AI platforms in providing accurate information to patients with HS.

Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS

The pivotal BE HEARD trials demonstratedbimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

Advances in HS Treatment with Chris Sayed, MD

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

Navigating Challenges and Inspiring Advocacy: A Pre-Med Student's Journey With HS

Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.